Prolongation of QT interval induced by electroconvulsive therapy is attenuated by landiolol.
OBJECTIVE
The objective of this study was to determine if landiolol, ultra short-acting beta adrenoceptor antagonist, attenuates the prolongation of QT interval caused by electroconvulsive therapy (ECT).


METHODS
Fifteen patients, scheduled to undergo ECT for the treatment of major depression disorder, were studied. In each patient, 2 sessions of ECT were picked up and randomly assigned to be administered with (treatment L) or without continuous infusion of landiolol (treatment C). Electroconvulsive therapy was administered under general anesthesia with propofol and suxamethonium. Raw electrocardiogram waves were obtained from anesthesia monitor and stored on a personal computer. Automated electrocardiogram analyzing software was used for the determination of QT interval.


RESULTS
The increase in corrected QT caused by suxamethonium was significantly smaller in treatment L (36.8 +/- 14.5 ms for treatment C vs 17.9 +/- 6.5 ms for treatment L; P < 0.001). The increase in corrected QT caused by ECT was also smaller in treatment L (72.3 +/- 23.1 ms for treatment C vs 54.6 +/- 17.9 ms for treatment L; P = 0.02).


CONCLUSIONS
The prolongation of QT interval caused by SUX and ECT was partially attenuated by landiolol.
Matsura
Masayo
M
Department of Anesthesiology, Aichi Gakuin University School of Dentistry, Nagoya, Japan.
Fujiwara
Yoshihiro
Y
Ito
Hiroshi
H
Kandatsu
Nobuhisa
N
Kato
Naoko
N
Harada
Jun
J
Komatsu
Toru
T
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000771:Anesthesia, Intravenous; D018686:Anesthetics, Intravenous; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D003866:Depressive Disorder / Q000523:psychology / Q000628:therapy; D004565:Electroconvulsive Therapy / Q000009:adverse effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008133:Long QT Syndrome / Q000209:etiology* / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009025:Morpholines / Q000627:therapeutic use*; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects; D011292:Premedication; D015742:Propofol; D013390:Succinylcholine / Q000009:adverse effects; D014508:Urea / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D018686:Anesthetics, Intravenous; D000889:Anti-Arrhythmia Agents; D009025:Morpholines; D009467:Neuromuscular Depolarizing Agents; C077049:landiolol; D014508:Urea; D013390:Succinylcholine; D015742:Propofol